Добірка наукової літератури з теми "Apolipoprotien C III"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Apolipoprotien C III".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Apolipoprotien C III"
Puchois, P., C. Luley, and P. Alaupovic. "Comparison of four procedures for separating apolipoprotein A- and apolipoprotein B-containing lipoproteins in plasma." Clinical Chemistry 33, no. 9 (September 1, 1987): 1597–602. http://dx.doi.org/10.1093/clinchem/33.9.1597.
Повний текст джерелаMärz, W., G. Schenk, and W. Gross. "Apolipoproteins C-II and C-III in serum quantified by zone immunoelectrophoresis." Clinical Chemistry 33, no. 5 (May 1, 1987): 664–69. http://dx.doi.org/10.1093/clinchem/33.5.664.
Повний текст джерелаVisvikis, S., M. F. Dumon, J. Steinmetz, T. Manabe, M. M. Galteau, M. Clerc, and G. Siest. "Plasma apolipoproteins in Tangier disease, as studied with two-dimensional electrophoresis." Clinical Chemistry 33, no. 1 (January 1, 1987): 120–22. http://dx.doi.org/10.1093/clinchem/33.1.120.
Повний текст джерелаHata, M., T. Ito, and K. Ohwada. "Kinetic analysis of apolipoproteins in postprandial hypertriglyceridaemia rabbits." Laboratory Animals 43, no. 2 (April 2009): 174–81. http://dx.doi.org/10.1258/la.2008.007004.
Повний текст джерелаMiller, Michael. "Apolipoprotein C-III." Arteriosclerosis, Thrombosis, and Vascular Biology 37, no. 6 (June 2017): 1013–14. http://dx.doi.org/10.1161/atvbaha.117.309493.
Повний текст джерелаHuff, Murray W., and Robert A. Hegele. "Apolipoprotein C-III." Circulation Research 112, no. 11 (May 24, 2013): 1405–8. http://dx.doi.org/10.1161/circresaha.113.301464.
Повний текст джерелаKohan, Alison B. "Apolipoprotein C-III." Current Opinion in Endocrinology & Diabetes and Obesity 22, no. 2 (April 2015): 119–25. http://dx.doi.org/10.1097/med.0000000000000136.
Повний текст джерелаWang, Wenyu, Piers Blackett, Sohail Khan, and Elisa Lee. "Apolipoproteins A-I, B, and C-III and Obesity in Young Adult Cherokee." Journal of Lipids 2017 (2017): 1–7. http://dx.doi.org/10.1155/2017/8236325.
Повний текст джерелаHuet, G., M. C. Dieu, A. Martin, G. Grard, J. M. Bard, P. Fossati, and P. Degand. "Heterozygous hypobetalipoproteinemia with fasting chylomicronemia." Clinical Chemistry 37, no. 2 (February 1, 1991): 296–300. http://dx.doi.org/10.1093/clinchem/37.2.0296.
Повний текст джерелаWang, C. S., W. J. McConathy, H. U. Kloer, and P. Alaupovic. "Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III." Journal of Clinical Investigation 75, no. 2 (February 1, 1985): 384–90. http://dx.doi.org/10.1172/jci111711.
Повний текст джерелаДисертації з теми "Apolipoprotien C III"
Clabé, Alain. "Apolipoprotéines C-II, C-III et E : mise au point et essai d'une technique de dosage immunonéphélémétrique." Bordeaux 2, 1993. http://www.theses.fr/1993BOR2P028.
Повний текст джерелаSEFRAOUI, MOHAMMED. "Les apolipoproteines a-iv, cii, c-iii et e : polymorphisme des apolipoproteines a-iv et e, quantification des apolipoproteines c-ii et c-iii o-2 chez les sujets hyperlipoproteinemiques." Lille 2, 1989. http://www.theses.fr/1989LIL2P262.
Повний текст джерелаMauger, Jean-François. "Apolipoptotéine C-III, taille des LDL et protéine C-réactive." Doctoral thesis, Université Laval, 2009. http://hdl.handle.net/20.500.11794/20954.
Повний текст джерелаCANDELIER, LAURENT. "Isolement et caracterisation des particules lipoproteiques plasmatiques lpb, lpb : e, lpb c-iii et lpb : c-iii : e. mise au point et utilisation d'une methode de chromatographie d'immunoaffinite sequentielle." Lille 2, 1989. http://www.theses.fr/1989LIL2P259.
Повний текст джерелаMauger, Jean-François. "Apolipoprotéine C-III, taille des LDL et protéine C-réactive. Études physiologiques en relation avec le syndrome métabolique." Thesis, Université Laval, 2009. http://www.theses.ulaval.ca/2009/26400/26400.pdf.
Повний текст джерелаKoska, Juraj, Hussein Yassine, Olgica Trenchevska, Shripad Sinari, Dawn C. Schwenke, Frances T. Yen, Dean Billheimer, Randall W. Nelson, Dobrin Nedelkov, and Peter D. Reaven. "Disialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetes." AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC, 2016. http://hdl.handle.net/10150/614755.
Повний текст джерелаEllena, Rachel A. "Antimicrobial and lipid binding properties of the C-terminal domain of apolipoprotein A-I determined using a novel apolipophorin III/apolipoprotein A-I (179-243) chimera." Thesis, California State University, Long Beach, 2016. http://pqdtopen.proquest.com/#viewpdf?dispub=10144827.
Повний текст джерелаApolipoprotein A-I (apoA-I) is an exchangeable apolipoprotein that constitutes the major protein component of high density cholesterol. ApoA-I is a two-domain protein comprising an N-terminal helix bundle and a less-structured C-terminal domain in the lipid-free state. In the present study, the contribution of the C-terminal domain to the lipid binding and antimicrobial activity of apoA-I was investigated using a chimeric construct in which the C-terminal domain of apoA-I (179-243) was attached to an insect apolipoprotein, Locusta migratoria apolipophorin III (apoLp-III), bearing cysteine substitutions for residues 20 and 149. Circular dichroism results were consistent with the addition of a poorly structured domain to apoLp-III and revealed the apoLp-III helix bundle was successfully closed under oxidizing conditions. Electrophoresis, fluorescence spectroscopy and an in vitro study using macrophage cells revealed that the C-terminal domain in itself was insufficient for efficient binding to lipid, lipopolysaccharide and phosphatidylglycerol vesicles. These results suggest the underlying mechanisms governing these interactions are potentiated by cooperativity between the N- and C-terminal domains of apoA-I.
Pan, Wenru. "Triglyceride rich lipoproteins and Apolipoprotein C-III in Atherosclerosis." Thesis, 2020. http://hdl.handle.net/2440/129639.
Повний текст джерелаThesis (Ph.D.) -- University of Adelaide, Adelaide Medical School, 2020
LIU, I. LIN, and 劉怡麟. "Association between hypertriglyceridemia and apolipoprotien C-III/lipoprotein lipase gene polymorphism in Taiwan Aborigines." Thesis, 2003. http://ndltd.ncl.edu.tw/handle/77919163595950444735.
Повний текст джерела高雄醫學大學
醫學研究所
91
Abstract Background - Hypertriglyceridemia(HTG) is a heterogeneous metabolic disorder. Effects of environmental factors and two genetic polymorphisms, an SstI polymorphism of Apolipoprotein C III gene and a Hind III polymorphism of lipoprotein lipase gene, on risk of HTG were analyzed in 250 Taiwan aborigines with or without HTG. Methods - This is a cross-sectional study of 250 southern Taiwan aborigines, which composed Paiwan tribe and Amis tribe, with 90 cases in the HTG group and 160 with normal serum triglycerides (NTG) recruited from community Health examinations. HTG is defined as > 150 mg/dl according to report by National Cholesterol Education Program (2001). Demographic data and dietary habits were collected by trained interviewers using structured questionaires. Polymerase chain reaction — restriction fragment length polymorphism (PCR — RFLP) was performed to define gene polymorphisms. Results - The respective SstI major allele (S1) and minor allele (S2) frequencies were 66.1﹪and 33.9﹪in HTG group and 73.6% and 26.4 % in NTG group (p<0.1). As analyzed exclusively in female subjects, frequencies of S2 allele was significantly higher (p<0.03) in HTG. The frequencies of the HindIII major allele (H+) and minor allele (H-) were similar between HTG (H+ 84.3﹪; H-:15.7﹪) and NTG (H+ 78.9%; H-:21.1%). Multiple logistic regression analysis reveals that Amis tribe, betel-chewing, starchy food, and plasma ApoC3concentrations were independently associated with risk of HTG. Furthermore, ApoC3 concentrations were increased (p<0.01) in a dose response manner among subjects with APOCIII s1s1, s1s2 and s2s2 genotypes accordingly. Conclusions- In conclusion, our analyses suggest that molecular variants of APOC III(Sst І) polymorphism may be associated risk of HTG in Taiwan Aborigines.
Perng, Tsae-Feng, and 彭彩鳳. "Effect of dietary fat and insulin on apolipoprotein C-II and apolipoprotein C-III gene expression in rats." Thesis, 2000. http://ndltd.ncl.edu.tw/handle/46926500178605193115.
Повний текст джерела靜宜大學
食品營養研究所
88
Hypertriglyceridemias are important risk factors for cardiovascular disease. Lipoprotein lipase (LPL, EC 3.1.1.34) plays an important role in lipid metabolism. The enzyme is activated by apolipoprotein C-II (ApoC-II) and inhibited by apolipoprotein C-III (ApoC-III). Because impaired LPL activity will lead to hypertriglyceridemia, therefore, the purpose of this research project was to study the effects of dietary fat and insulin on apoC-II and apoC-III gene expression. First, forty-eight male SD rats were divided into 6 groups and fed diets containing 7.5%, 15% and 30% of lard and soybean oil for 2 weeks, respectively. The concentrations of fasting total cholesterol (TC) and triglyceride (TG) in blood and the concentrations of apoC-II and apoC-III mRNA in liver and intestine were measured. After 2 weeks, fasting total cholesterol was not affected by the regimen, however, the concentrations of serum triglyceride in rats fed 30% soybean oil diet was significantly lower than those rats fed 7.5% and 15﹪soybean oil diet. Second, twenty-eight male Wistar rats were divided into 4 groups: control, diabetic group (streptozotocin-induced), insulin-treated for 1d group and insulin treated for 3d group. At the end of each period, the concentrations of serum glucose and triglyceride, and the concentrations of apoC-II and apoC-III mRNA in liver and intestine were measured. After treated with insulin, blood glucose and triglyceride levels were decreased significantly in diabetic rats, compared to their basal levels. However, both hepatic and intestinal apo C-II and apo C-III mRNA levels were not affected by insulin treatment. The results of this study suggest that intestinal apo C-II mRNA levels could be affected by the amount of dietary fat. It is possible that insulin is not a major hormonal factor, to regulate apo C-II and apo C-III gene expression in rats.
Частини книг з теми "Apolipoprotien C III"
Lackner, K. J., and D. Peetz. "Apolipoprotein C-III." In Lexikon der Medizinischen Laboratoriumsdiagnostik, 1. Berlin, Heidelberg: Springer Berlin Heidelberg, 2018. http://dx.doi.org/10.1007/978-3-662-49054-9_270-1.
Повний текст джерелаLackner, K. J., and D. Peetz. "Apolipoprotein C-III." In Springer Reference Medizin, 191. Berlin, Heidelberg: Springer Berlin Heidelberg, 2019. http://dx.doi.org/10.1007/978-3-662-48986-4_270.
Повний текст джерелаHumphries, Steve, Vilmundur Gudnason, Hiroko Paul-Hayase, N. Saha, and Maryvonne Rosseneu. "Identification of Common Genetic Polymorphisms that Determine Plasma Levels of ApoAI and HDL-C." In Human Apolipoprotein Mutants III, 247–56. Berlin, Heidelberg: Springer Berlin Heidelberg, 1993. http://dx.doi.org/10.1007/978-3-642-84634-2_22.
Повний текст джерелаOrdovas, Jose M., Dianne C. King, and Ernst J. Schaefer. "Familial Apolipoprotein A-I, C-III and A-IV Deficiency." In Human Apolipoprotein Mutants 2, 157–59. Boston, MA: Springer US, 1989. http://dx.doi.org/10.1007/978-1-4615-9549-6_19.
Повний текст джерелаFerrell, R. E., M. I. Kamboh, B. S. Sepehrnia, L. L. Adams-Campbell, and K. M. Weiss. "Genetic Variation in the Apolipoproteins C-II and C-III." In Advances in Experimental Medicine and Biology, 81–85. Boston, MA: Springer US, 1988. http://dx.doi.org/10.1007/978-1-4613-0733-4_11.
Повний текст джерелаFruchart, J. C., V. Clavey, G. Luc, J. Dallongeville, B. Staels, and J. Auwerx. "Apolipoprotein C-III, An Important Player in Lipoprotein Metabolism." In Drugs Affecting Lipid Metabolism, 631–38. Dordrecht: Springer Netherlands, 1996. http://dx.doi.org/10.1007/978-94-009-0311-1_74.
Повний текст джерелаNorum, Robert A., Trudy M. Forte, Petar Alaupovic, and Henry N. Ginsberg. "Clinical Syndrome and Lipid Metabolism in Hereditary Deficiency of Apolipoproteins A-I and C-III, Variant 1." In Lipoprotein Deficiency Syndromes, 137–49. Boston, MA: Springer US, 1986. http://dx.doi.org/10.1007/978-1-4684-1262-8_13.
Повний текст джерелаKashyap, Moti L. "[12] Immunochemical methods for quantification of human apolipoprotein C-III." In Methods in Enzymology, 208–18. Elsevier, 1996. http://dx.doi.org/10.1016/s0076-6879(96)63014-6.
Повний текст джерелаJackson, Richard L., and George Holdsworth. "[14] Isolation and properties of human apolipoproteins C-I, C-II, and C-III." In Methods in Enzymology, 288–97. Elsevier, 1986. http://dx.doi.org/10.1016/0076-6879(86)28074-x.
Повний текст джерелаKarathanasis, Sotirios K., Vassilis I. Zannis, and Jan L. Breslow. "[41] Characterization of the apolipoprotein A-I—C-III gene complex." In Methods in Enzymology, 712–26. Elsevier, 1986. http://dx.doi.org/10.1016/0076-6879(86)28101-x.
Повний текст джерела